• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Outpatient Inhaled Nitric Oxide in a Patient with Vasoreactive Idiopathic Pulmonary Arterial Hypertension and COVID-19 Infection.

作者信息

Zamanian Roham T, Pollack Charles V, Gentile Michael A, Rashid Moira, Fox John Christian, Mahaffey Kenneth W, de Jesus Perez Vinicio

机构信息

Stanford University School of MedicineStanford, California.

Vera Moulton Wall Center for Pulmonary Vascular DiseaseStanford, California.

出版信息

Am J Respir Crit Care Med. 2020 Jul 1;202(1):130-132. doi: 10.1164/rccm.202004-0937LE.

DOI:10.1164/rccm.202004-0937LE
PMID:32369396
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7328330/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4eb6/7328330/6ad353dd677f/rccm.202004-0937LEf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4eb6/7328330/6ad353dd677f/rccm.202004-0937LEf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4eb6/7328330/6ad353dd677f/rccm.202004-0937LEf1.jpg

相似文献

1
Outpatient Inhaled Nitric Oxide in a Patient with Vasoreactive Idiopathic Pulmonary Arterial Hypertension and COVID-19 Infection.一名患有血管反应性特发性肺动脉高压和新冠病毒感染患者的门诊吸入一氧化氮治疗
Am J Respir Crit Care Med. 2020 Jul 1;202(1):130-132. doi: 10.1164/rccm.202004-0937LE.
2
High dose folic acid is a potential treatment for pulmonary hypertension, including when associated with COVID-19 pneumonia.大剂量叶酸是肺动脉高压的一种潜在治疗方法，包括与 COVID-19 肺炎相关的情况。
Med Hypotheses. 2020 Oct;143:110142. doi: 10.1016/j.mehy.2020.110142. Epub 2020 Jul 26.
3
Effect of almitrine bismesylate and inhaled nitric oxide on oxygenation in COVID-19 acute respiratory distress syndrome.二甲磺酸阿米三嗪与吸入一氧化氮对新型冠状病毒肺炎急性呼吸窘迫综合征氧合的影响
Anaesth Crit Care Pain Med. 2020 Aug;39(4):471-472. doi: 10.1016/j.accpm.2020.05.014. Epub 2020 Jun 4.
4
Ventilatory support recommendations in children with Sars-CoV-2.2019冠状病毒病（Sars-CoV-2）感染儿童的通气支持建议
Rev Assoc Med Bras (1992). 2020 Apr;66(4):528-533. doi: 10.1590/1806-9282.66.4.528.
5
Inhaled nitric oxide treatment in spontaneously breathing COVID-19 patients.对自主呼吸的新冠肺炎患者进行吸入一氧化氮治疗。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620933510. doi: 10.1177/1753466620933510.
6
Clinical course of COVID-19 in pulmonary arterial hypertension patients.肺动脉高压患者感染新型冠状病毒肺炎的临床病程
Rev Esp Cardiol (Engl Ed). 2020 Sep;73(9):775-778. doi: 10.1016/j.rec.2020.05.015. Epub 2020 May 30.
7
Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe?用于肺动脉高压和新冠肺炎的内皮素受体拮抗剂：是友还是敌？
J Heart Lung Transplant. 2020 Jul;39(7):729-730. doi: 10.1016/j.healun.2020.04.007. Epub 2020 Apr 17.
8
Covid-19: The last call for telepsychiatry.新冠疫情：远程精神病学的最后呼吁。
Acta Biomed. 2020 Jul 28;91(3):ahead of print. doi: 10.23750/abm.v91i3.10337.
9
Alterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection.轻度症状的 SARS-CoV-2 感染门诊患者的嗅觉或味觉改变。
JAMA. 2020 May 26;323(20):2089-2090. doi: 10.1001/jama.2020.6771.
10
PRACTITIONER APPLICATION: Rapid Systemwide Implementation of Outpatient Telehealth in Response to the COVID-19 Pandemic.从业者应用：为应对新冠疫情而在全系统快速实施门诊远程医疗
J Healthc Manag. 2020 Nov-Dec;65(6):452-454. doi: 10.1097/JHM-D-20-00273.

引用本文的文献

1
Inhaled nitric oxide as an independent intervention to lower the risk of bronchopulmonary dysplasia in preterm infants (< 33 weeks) with pulmonary hypertension within the initial 3 days of life.吸入一氧化氮作为一种独立干预措施，用于降低出生后最初3天内患有肺动脉高压的早产儿（<33周）发生支气管肺发育不良的风险。
Sci Rep. 2025 Jul 2;15(1):22517. doi: 10.1038/s41598-025-06055-0.
2
The Potential Role of Nitric Oxide as a Therapeutic Agent against SARS-CoV-2 Infection.一氧化氮作为治疗 SARS-CoV-2 感染的潜在药物的作用。
Int J Mol Sci. 2023 Dec 5;24(24):17162. doi: 10.3390/ijms242417162.
3
Amino acids, post-translational modifications, nitric oxide, and oxidative stress in serum and urine of long COVID and ex COVID human subjects.

本文引用的文献

1
Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic.新型冠状病毒肺炎（COVID-19）大流行期间肺动脉高压患者的护理
Pulm Circ. 2020 Apr 29;10(2):2045894020920153. doi: 10.1177/2045894020920153. eCollection 2020 Apr-Jun.
2
COVID-19 Does Not Lead to a "Typical" Acute Respiratory Distress Syndrome.新冠病毒肺炎不会导致“典型的”急性呼吸窘迫综合征。
Am J Respir Crit Care Med. 2020 May 15;201(10):1299-1300. doi: 10.1164/rccm.202003-0817LE.
3
Symptom severity and its effect on health-related quality of life over time in patients with pulmonary hypertension: a multisite longitudinal cohort study.
新冠康复者和长期新冠患者血清及尿液中的氨基酸、翻译后修饰、一氧化氮和氧化应激
Amino Acids. 2023 Sep;55(9):1173-1188. doi: 10.1007/s00726-023-03305-1. Epub 2023 Jul 29.
4
Advanced Nitric Oxide Generating Nanomedicine for Therapeutic Applications.用于治疗应用的高级一氧化氮生成纳米医学。
ACS Nano. 2023 May 23;17(10):8935-8965. doi: 10.1021/acsnano.3c02303. Epub 2023 May 1.
5
Human Endogenous Retrovirus, SARS-CoV-2, and HIV Promote PAH via Inflammation and Growth Stimulation.人类内源性逆转录病毒、SARS-CoV-2 和 HIV 通过炎症和生长刺激促进 PAH。
Int J Mol Sci. 2023 Apr 18;24(8):7472. doi: 10.3390/ijms24087472.
6
Clinical Course of Two Patients with COVID-19 Respiratory Failure After Administration of the Anticancer Small Molecule, RRx-001.两名新冠肺炎呼吸衰竭患者在给予抗癌小分子药物RRx-001后的临床病程
Int Med Case Rep J. 2022 Dec 15;15:735-738. doi: 10.2147/IMCRJ.S389690. eCollection 2022.
7
The Renin-Angiotensin-Aldosterone System, Nitric Oxide, and Hydrogen Sulfide at the Crossroads of Hypertension and COVID-19: Racial Disparities and Outcomes.肾素-血管紧张素-醛固酮系统、一氧化氮和硫化氢在高血压和 COVID-19 的交叉点：种族差异和结果。
Int J Mol Sci. 2022 Nov 11;23(22):13895. doi: 10.3390/ijms232213895.
8
Pharmacologic therapies of ARDS: From natural herb to nanomedicine.急性呼吸窘迫综合征的药物治疗：从天然草药到纳米药物。
Front Pharmacol. 2022 Oct 28;13:930593. doi: 10.3389/fphar.2022.930593. eCollection 2022.
9
Acute Respiratory Distress Syndrome and the Use of Inhaled Pulmonary Vasodilators in the COVID-19 Era: A Narrative Review.急性呼吸窘迫综合征与COVID-19时代吸入性肺血管扩张剂的应用：一篇叙述性综述
Life (Basel). 2022 Nov 2;12(11):1766. doi: 10.3390/life12111766.
10
Utility of NO and HS donating platforms in managing COVID-19: Rationale and promise.NO 和 HS 供体平台在管理 COVID-19 中的效用：原理和前景。
Nitric Oxide. 2022 Nov 1;128:72-102. doi: 10.1016/j.niox.2022.08.003. Epub 2022 Aug 24.
肺动脉高压患者症状严重程度及其对健康相关生活质量随时间的影响：一项多中心纵向队列研究。
BMJ Open Respir Res. 2018 Mar 1;5(1):e000263. doi: 10.1136/bmjresp-2017-000263. eCollection 2018.
4
Inhaled nitric oxide therapy for pulmonary disorders of the term and preterm infant.吸入一氧化氮治疗足月儿和早产儿的肺部疾病。
Semin Perinatol. 2016 Oct;40(6):356-369. doi: 10.1053/j.semperi.2016.05.007.
5
Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults.吸入一氧化氮用于儿童和成人急性呼吸窘迫综合征（ARDS）的治疗
Cochrane Database Syst Rev. 2016 Jun 27;2016(6):CD002787. doi: 10.1002/14651858.CD002787.pub3.
6
Inhaled nitric oxide to improve oxygenation for safe critical care transport of adults with severe hypoxemia.吸入一氧化氮以改善严重低氧血症成人患者在安全重症监护转运过程中的氧合情况。
Am J Crit Care. 2015 Mar;24(2):110-7. doi: 10.4037/ajcc2015570.
7
ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association.美国心脏病学会基金会/美国心脏协会2009年肺动脉高压专家共识文件：美国心脏病学会基金会专家共识文件特别工作组及美国心脏协会报告：与美国胸科医师学会、美国胸科学会及肺动脉高压协会合作制定。
Circulation. 2009 Apr 28;119(16):2250-94. doi: 10.1161/CIRCULATIONAHA.109.192230. Epub 2009 Mar 30.
8
Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: a rescue trial in Beijing.吸入一氧化氮治疗严重急性呼吸综合征：在北京进行的一项抢救试验。
Clin Infect Dis. 2004 Nov 15;39(10):1531-5. doi: 10.1086/425357. Epub 2004 Oct 22.
9
Improvement in exercise capacity with nitric oxide inhalation in patients with precapillary pulmonary hypertension.毛细血管前性肺动脉高压患者吸入一氧化氮后运动能力的改善
Circulation. 2000 May 2;101(17):2066-70. doi: 10.1161/01.cir.101.17.2066.